SEARCH THE BLOG:
25
Sep-2017

Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics

_, News   /   Tags: , , ,

Fusion Pharmaceuticals, a Hamilton-based clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD.

Fusion Pharmaceuticals is a spinout from the Centre for Probe Development and Commercialization (CPDC), which is a  Centre of Excellence for Commercialization and Research (CECR) located at McMaster University

To read the full press release, click here

0

 likes / 0 Comments
Share this post:

Archives

> <
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec